Liver Cancer
Copyright ©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Apr 14, 2005; 11(14): 2072-2079
Published online Apr 14, 2005. doi: 10.3748/wjg.v11.i14.2072
Figure 1
Figure 1 IHC staining of HSP in DN and HCC (original magnification, ×100). A: Rare immunoreactivity for HSP27 in high-grade DN; B: 25% immunoreactivity for HSP27 in early HCC. The borders between early HCC and non-tumorous liver are indicated by arrowheads; C: 96% immunoreactivity for HSP60 in HCC Grade II; D: 30% immunoreactivity for HSP70 in HCC Grade I. Bile duct epithelium shows cytoplasmic immunoreactivity (arrow); E: 35% immunoreactivity for HSP90 in HCC Grade II; F: Rare immunoreactivity for GRP78 in low-grade DN; G: 10% immunoreactivity for GRP78 in HCC Grade I; H: 93% immunoreactivity for GRP78 in HCC Grade III; I: 15% immunoreactivity for GRP94 in high-grade DN; J: 95% immunoreactivity for GRP94 in HCC Grade III. N, non-tumorous liver.